Evidence map›Paper›PMID 34875340›Full record

ReviewFree radical biology & medicine2022

Breaking barriers: Neurodegenerative repercussions of radiotherapy induced damage on the blood-brain and blood-tumor barrier.

Barrett D Allen, Charles L Limoli

Open access · hybridAbstract readReview
In one paragraph

Review in Free radical biology & medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. GlioblastomaACS biomaterials science & engineering · 2026
    Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Kinin BPharmaceuticals (Basel, Switzerland) · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Barrett D AllenDepartment of Radiation Oncology, University of California, Irvine, CA, 92697, USA.
Charles L LimoliDepartment of Radiation Oncology, University of California, Irvine, CA, 92697, USA. Electronic address: climoli@uci.edu.
University of California, Irvine · US

Funding

Project 4: Mechanistic Basics of FLASH Effect: Role of O2P01CA244091 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI LIMOLI, CHARLES · 2020 to 2024
$9.6M
Translational strategies for protecting the brain against radio- and chemotherapyR01NS074388 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI LIMOLI, CHARLES · 2011 to 2020
$3.5M
Improving pediatric brain tumor treatments using FLASH radiotherapyR01CA254892 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Charles Limoli · 2021 to 2026
$2.5M
NCI NIH HHS P01 CA244091NCI NIH HHS R01 CA254892NINDS NIH HHS R01 NS074388
6 · The paper itself

Abstract

Exposure to radiation during the treatment of CNS tumors leads to detrimental damage of the blood brain barrier (BBB) in normal tissue. Effects are characterized by leakage of the vasculature which exposes the brain to a host of neurotoxic agents potentially leading to white matter necrosis, parenchymal calcification, and an increased chance of stroke. Vasculature of the blood tumor barrier (BTB) is irregular leading to poorly perfused and hypoxic tissue throughout the tumor that becomes resistant to radiation. While current clinical applications of cranial radiotherapy use dose fractionation to reduce normal tissue damage, these treatments still cause significant alterations to the cells that make up the neurovascular unit of the BBB and BTB. Damage to the vasculature manifests as reduction in tight junction proteins, alterations to membrane transporters, impaired cell signaling, apoptosis, and cellular senescence. While radiotherapy treatments are detrimental to normal tissue, adapting combined strategies with radiation targeted to damage the BTB could aid in drug delivery. Understanding differences between the BBB and the BTB may provide valuable insight allowing clinicians to improve treatment outcomes. Leveraging this information should allow advances in the development of therapeutic modalities that will protect the normal tissue while simultaneously improving CNS tumor treatments.

Indexed as

Blood-Brain BarrierCentral Nervous System NeoplasmsApoptosisBiological TransportDrug Delivery SystemsHumansBlood brain barrierBlood tumor barrierNeurovascular unitRadiation

Identifiers

PMID34875340
PMCPMC8925982
OpenAlexW4200265252

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.